Cellectar Reports Q3 2026 Financial Results and Clinical Progress for iopofosine I-131
Cellectar (CLRB) reported its third-quarter 2026 financial results, highlighted by a net loss of $8.0 million ($0.46 per share) driven by increased research and development spending. The company's cash position improved to $24.6 million as of September 30, 2026, following an oversubscribed financing in May 2026. Management confirmed a cash runway extending into the second quarter of 2027, which is intended to fund the initiation of their confirmatory Phase III trial and upcoming NDA submission. Clinically, Cellectar presented strong data for iopofosine I-131 in Waldenström's macroglobulinemia patients previously treated with BTK inhibitors, showing an 87.5% overall response rate in that subgroup. The company plans to submit a New Drug Application (NDA) in the first half of 2027 and has strategically deferred European regulatory submissions by nine months to protect potential U.S. pricing. Additionally, initial dosimetry data for their triple-negative breast cancer program is expected in Q4 2026.
Topics: biotechnology clinical trials earnings report financial results